Mind Medicine (MNMD) said Tuesday that it dosed the first patient in the phase 3 study evaluating MM120 orally disintegrating tablet or ODT, for the treatment of major depressive disorder.
The study will evaluate 100 microgram doses of the drug candidate for efficacy and safety compared with placebo in about 140 participants in the US, according to the company.
The company said the trial will consist of a 12-week randomized, double blind, placebo-controlled study followed by a 40-week open-label period. Top-line data from the first part is expected in the second half of 2026.
MM120 ODT is a pharmaceutically optimized form of lysergide D-tartrate or LSD, Mind Medicine added.
Shares of the company were up 3.2% in recent trading.
Price: 5.78, Change: +0.23, Percent Change: +4.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。